The workplan includes 7 inter-related work packages (WPs) that are aimed to deliver the first paediatric formulation of a macrocyclic lactone suitable for use in children from the age of one who require treatment for onchocerciasis, or, potentially four other neglected diseases:

WP1: Establish moxidectin’s paediatric formulation target product characteristics

WP2: ‘End-user’ feedback obtained on ‘End-user facing’ paediatric formulation target product characteristics

WP3: MDGH-Funded Manufacture of selected formulations

WP4: Determine the bioequivalence of the selected paediatric formulation with the approved 2 mg tablet formulation in clinical study in Ghana

WP5: MDGH-Funded Population pharmacokinetic modelling for younger children

WP6: Project Management

WP7: Communication and Dissemination